A link between drug efficacy and metabolism through CYP2D6 is supported by recent animal and clinical studies, including the association of CYP2D6 poor metaboliser phenotype status with primaquine failure in controlled human malaria infections with P. vivax2,8. The gene discussed is CYP2D6; the disease is infection.